A5103107065- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Brain Metastases and Treatment
- Cell Image Analysis Techniques
- Virus-based gene therapy research
- Glioma Diagnosis and Treatment
- Cell Adhesion Molecules Research
- Ubiquitin and proteasome pathways
- Endoplasmic Reticulum Stress and Disease
- Histone Deacetylase Inhibitors Research
- Heat shock proteins research
- Nanoplatforms for cancer theranostics
- Epigenetics and DNA Methylation
University of Cincinnati
2023
NYU Langone Health
2014-2017
New York University
2015-2017
Eastern Cooperative Oncology Group
2015-2017
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2015
Abstract Purpose: The application of pan-cancer next-generation sequencing panels in the clinical setting has facilitated identification low frequency somatic mutations and testing new therapies solid tumors using "basket trial" scheme. However, little consideration been given to relevance nonsynonymous germline variants, which are likely be uncovered may relevant prognostication prediction treatment response. Experimental Design: We analyzed matched tumor normal DNA from 34 melanoma...
9065 Background: The concept of immune cell exhaustion in the context metastatic melanoma has been reinforced by success immunotherapies targeting markers CTLA-4 and PD-1. Natural Killer (NK) exhaustion, characterized an up-regulation inhibitory receptors loss function, was described melanoma. Ipilimumab (IPI - anti-CTLA-4) improves anti-tumor T activity achieves response rates 15-20%, however effect IPI on NK cells is unknown. In this project, we studied phenotype from patients how it...
3019 Background: Combination of anti-CTLA-4 and radiation therapy with or without steroids are common in the management melanoma patients. However, their clinical results effects on immunity have not been examined depth. In this study we observe immune response patients treated anti-CTLA-4/radiation anti-CTLA-4/steroids. Methods: We anlayzed a cohort antibody at NYU Medical Center. differences overall survival using log-rank test 1) therapy; 2) steroids. Corticosteroids were administered to...
9534 Background: Efforts to identify targeted therapies that can improve treatment outcome in metastatic ALM have been unsuccessful. In a previous genomic screening, we identified copy number amplification of the histone methyltransferase EZH2 47% cases, higher frequency than previously reported cutaneous melanomas (CM) (5%). Here, tested hypothesis increased expression contributes progression and may confer selective sensitivity inhibition. Methods: was examined by immunohistochemistry...
Abstract Background: Molecularly targeted therapy is improving response rates and overall survival in subsets of melanoma patients. However, for triple negative patients (BRAF, NRAS c-KIT wild type) not yet defined. In addition, new evidence suggests that germline variants may have an impact progression to therapy. this study, we attempt define the utility a recently developed clinical assay encompasses sequencing 50 genes with known on cancer progression. Methods: We used AmpliSeq Cancer...
Abstract Background: BRAF and NRAS are well-established driver oncogenes in melanoma. Mutations the promoter region of telomerase reverse transcriptase gene (TERT) increase expression have been identified at high rates metastatic melanoma, rarely familial One recent study found an association between TERT mutations or mutations. We developed mutation-specific assays to detect V600 Q61 along with C228T C250T identify prevalence these melanoma tumor samples, BRAF/NRAS mutations, potential use...
9095 Background: Molecularly targeted therapy is improving response rates and overall survival in subsets of melanoma patients. However, for “triple negative” patients (BRAF, NRAS c-KIT wild type) not yet defined. In addition, new evidence suggests that germline variants may have an impact progression to therapy. this study, we attempt define the utility a recently developed clinical assay encompasses sequencing 50 genes with known on cancer progression. Methods: We used AmpliSeq Cancer...
9058 Background: Older ageat diagnosis has been shown to be an independent negative prognostic factor in melanoma. Nevertheless, no biological basis for the impact of age on melanoma defined. In this study, we examined patient cellular immune response as well immunotherapy treatment adjuvant setting a well-studied cohort patients. Methods: A prospectively-enrolled patients presenting with stage III at NYU was studied. Associations between and presence tumor-infiltrating lymphocytes (TILs),...
9099 Background: Recent success of immunotherapies targeting the exhaustion markers CTLA-4 and PD-1 has inforced role CD8+T cell in advanced melanoma patients. T exhaustion, been extensively studied, however little is known about NK same context. In this project, we defined cells phenotype different stages to examine its progression. Methods: were purified from peripheral blood a prospectively-enrolled cohort 100 patients: stage I (n=56), II (n=21) III/IV (n=23); addition 25 healthy donors....
e20042 Background: TILs in primary melanomas may represent a surrogate of anti-tumor immune response, yet debate exists if TIL grade offers independent prognostication. In large, prospectively accrued, well-characterized patient (pt) cohort, we examined quantitative detection contributes to improved outcome predictions and tested germline variants are associated with grade. Methods: We studied 1,241 pts cutaneous melanoma presenting NYU from 2002-13 (median f/u 3.9 years). were graded as...
9070 Background: Median survival of MBM pts is significantly shorter than with extra-cranial metastases. However, a subset exhibit extended survival. Radiation therapy (RT - radiosurgery and whole-brain radiation) used to treat recent data by several groups including ours demonstrate that RT may potentiate response immunotherapies inducing an immunological tumor cell death. In this study, we investigate the immunomodulator effect on tissue attempt identify profile associated improved...
<p>Our Ion Torrent targeted sequencing assay consists of a single ultraplex PCR reaction with primer sets for 207 amplicons. Data were filtered to exclude all synonymous and intronic variants. A quality score cutoff 100 an allele frequency >5 applied eliminate low artifacts.</p>
<p>Kaplan-Meier analysis shows no significant difference in overall survival of melanoma patients from the validation cohort based on KDR status (TA,AA: Q472H variant, TT: WT variant).</p>
<p>Somatic mutations (top column) identified by Ion Torrent sequencing of the pilot melanoma cohort are listed for each patient (left hand column).</p>
<p>Our Ion Torrent targeted sequencing assay consists of a single ultraplex PCR reaction with primer sets for 207 amplicons. Data were filtered to exclude all synonymous and intronic variants. A quality score cutoff 100 an allele frequency >5 applied eliminate low artifacts.</p>
<p>Sequencing data of paired primary/metastatic tumor samples from two patients.</p>
<p>Kaplan-Meier analysis shows no significant difference in overall survival of melanoma patients from the validation cohort based on KDR status (TA,AA: Q472H variant, TT: WT variant).</p>
<p>Clinically relevant somatic mutations identified in WT melanoma patients the pilot cohort</p>
<p>Somatic mutations (top column) identified by Ion Torrent sequencing of the pilot melanoma cohort are listed for each patient (left hand column).</p>
<div>Abstract<p><b>Purpose:</b> The application of pan-cancer next-generation sequencing panels in the clinical setting has facilitated identification low frequency somatic mutations and testing new therapies solid tumors using "basket trial" scheme. However, little consideration been given to relevance nonsynonymous germline variants, which are likely be uncovered may relevant prognostication prediction treatment response.</p><p><b>Experimental...
<div>Abstract<p><b>Purpose:</b> The application of pan-cancer next-generation sequencing panels in the clinical setting has facilitated identification low frequency somatic mutations and testing new therapies solid tumors using "basket trial" scheme. However, little consideration been given to relevance nonsynonymous germline variants, which are likely be uncovered may relevant prognostication prediction treatment response.</p><p><b>Experimental...